Kazia Therapeutics Ltd (KZA) reported that Memorial Sloan Kettering Cancer Center in New York, NY will investigate the potential use of Kazia's investigational new drug, GDC-0084, in combination with radiotherapy in a phase I clinical trial for cancer that has spread to the brain (brain metastases and leptomeningeal metastases)
http://crweworld.com/article/news-provided-by-pr-newswire/1173125/kazia-to-test-gdc-0084-with-radiotherapy-in-phase-i-clinical-trial-at-leading-us-cancer-center
